Disease · MONDO_0006939
Comparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 11 of 11
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Sulopenem vs Ertapenem: deaths from any cause | 2 of 697 | 0 of 698 | 1,395 | NCT03357614 | Trial comparisons |
| Sulopenem vs Ertapenem: serious adverse events | 14 of 697 | 6 of 698 | 1,395 | NCT03357614 | Trial comparisons |
| CXA-201 as Treatment for cUTI vs Levofloxacin as Treatment for cUTI: serious adverse events | 15 of 533 | 18 of 535 | 1,068 | NCT01345929 | Trial comparisons |
| Sulopenem vs Ertapenem: Percentage of Participants With Overall Success | 301 of 444 | 325 of 440 | 884 | NCT03357614 | Trial comparisons |
| Sulopenem vs Ertapenem: Percentage of Participants With Microbiologic Success | 316 of 444 | 343 of 440 | 884 | NCT03357614 | Trial comparisons |
| Ceftolozane/Tazobactam vs Meropenem: deaths from any cause | 0 of 101 | 0 of 33 | 134 | NCT03230838 | Trial comparisons |
| Ceftolozane/Tazobactam vs Meropenem: Number of Participants Discontinuing Study Therapy Due to AE | 1 of 100 | 0 of 33 | 133 | NCT03230838 | Trial comparisons |
| Ceftolozane/Tazobactam vs Meropenem: Number of Participants With ≥1 Adverse Events (AEs) | 59 of 100 | 20 of 33 | 133 | NCT03230838 | Trial comparisons |
| Ceftolozane/Tazobactam vs Meropenem: serious adverse events | 3 of 100 | 2 of 33 | 133 | NCT03230838 | Trial comparisons |
| CXA-101 vs Ceftazidime: serious adverse events | 1 of 85 | 0 of 42 | 127 | NCT00921024 | Trial comparisons |
| Flomoxef vs Cefepime: serious adverse events | 0 of 6 | 0 of 7 | 13 | NCT02302092 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006939/comparisons